Centene Corp evaluates its strategy as US health coverage needs evolve
Centene Corp is re-evaluating its strategy and cost structure in response to the changing regulatory and reimbursement landscape within the US managed care sector. The company primarily focuses on government-sponsored health programs like Medicaid, Medicare, and Affordable Care Act marketplace plans, necessitating strict operational discipline and effective risk management. Centene's business model integrates health plan administration, provider network management, and care coordination to provide comprehensive health solutions.
Cencora Inc. highlights its role in pharmaceutical distribution. Investors watch the company’s evo
Cencora Inc. is a major player in pharmaceutical distribution and healthcare services, with investors closely watching its evolving strategy. The company's extensive distribution network and focus on value-added healthcare services position it to capitalize on long-term trends like aging populations and complex new therapies. Cencora's stock performance is influenced by drug spending trends, regulatory developments, and its ability to integrate technology for efficiency and enhanced services.
Health Insurance Providers Stocks Q1 Recap: Benchmarking Centene (NYSE:CNC)
This article reviews the Q1 earnings for health insurance providers, highlighting Centene (NYSE:CNC) as a top performer. It discusses Centene's strong revenue and EPS beat, along with CVS Health's exceptional quarter. Conversely, Cencora (NYSE:COR) is noted for a weaker performance, while Clover Health (NASDAQ:CLOV) and Progyny (NASDAQ:PGNY) also showed strong results and growth.
Steve Collis: Pharmaceutical Distribution Leader and Former Chairman, President, and CEO of Cencora
This article details the career of Steve Collis, former President and CEO of Cencora (formerly AmerisourceBergen). It highlights his 13-year tenure where he significantly grew the company's revenue and global presence through strategic acquisitions and diversification. Collis is recognized for his purpose-driven leadership and for transforming Cencora into a leading global healthcare services company.
Enterprise value to revenue forward of Cencora, Inc. – NYSE:COR
This article focuses on the enterprise value to revenue forward metric for Cencora, Inc. (NYSE: COR). It appears to be a stub or a placeholder, as no specific financial data or analysis is provided beyond stating the company and the metric in question.
Enterprise value to revenue forward of Cencora, Inc. – MIL:1COR
This page from TradingView displays financial information for Cencora, Inc. (MIL:1COR), specifically focusing on its enterprise value to revenue forward. The content indicates the stock is traded on Euronext Milan, with market data provided by ICE Data Services and reference data by FactSet.
Cencora (COR) Could Be 15% Undervalued As Earnings Date Nears
Cencora (COR) is approaching its fiscal third-quarter earnings release on August 5, 2026, with current analysis suggesting it might be undervalued by 15.4%. The company's stock has shown strong long-term performance, and its investments in digital infrastructure are expected to drive higher margins and operating income. However, potential risks include increased regulatory scrutiny on drug pricing and heightened competition in specialty distribution.
Cencora (COR) Could Be 15% Undervalued As Earnings Date Nears
Cencora (COR) is approaching its fiscal third-quarter earnings release on August 5, 2026, with current analysis suggesting the stock is 15.4% undervalued at its last closing price of $296.51 against a fair value of $350.58. The company's investment in digital infrastructure and advanced analytics is expected to drive higher net margins, although regulatory scrutiny on drug pricing and competition pose potential risks. Investors are encouraged to review both the potential rewards and warning signs associated with Cencora.
Jim Cramer on Cardinal Health: “It’s Been a Real Stalwart, and I Don’t Think It’s Done”
Jim Cramer expressed confidence in Cardinal Health (NYSE: CAH), recommending it to investors and stating that the stock deserves to trade higher despite a recent rotation out of healthcare. He highlighted the company's strong performance in a recent quarter. Cardinal Health supplies branded and generic medicines, and medical products.
Jim Cramer on Cardinal Health: “It’s Been a Real Stalwart, and I Don’t Think It’s Done”
Jim Cramer highlighted Cardinal Health (NYSE: CAH) as a strong stock that deserves to trade higher, despite being obscured by a recent healthcare sector rotation. He emphasized the company's "great quarter" and its position as a "real stalwart." Cramer also mentioned an earlier implosion of the stock that concerned him, but still believes in its potential going forward.
Jim Cramer on Cardinal Health: “It’s Been a Real Stalwart, and I Don’t Think It’s Done”
Jim Cramer expressed confidence in Cardinal Health (NYSE: CAH), recommending it among healthcare stocks that deserve to trade higher. He highlighted its strong performance, despite a recent market rotation out of healthcare, and noted that it is held in his Trust. Cramer believes the stock is a "stalwart" and has further upside potential.
Is Cardinal Health (CAH) Fully Valued After Its Russell Index Removal?
Cardinal Health (CAH) was removed from several Russell indices following strong share price performance, leading investors to re-evaluate the stock. While Simply Wall St's narrative suggests it's slightly undervalued at $245.27, its P/E ratio of 36x is higher than the industry average, signaling potential valuation risk. Investors are encouraged to assess the full picture of the company's rewards and risks.
MCK - Mckesson Corp Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for McKesson Corp (MCK). It includes current stock performance metrics, valuation ratios, dividend information, and insider and institutional ownership percentages, alongside various profitability and efficiency ratios.
Cencora Inc. focuses on healthcare distribution scale as investors assess long-term growth prospects
Cencora Inc. is a major global pharmaceutical distributor leveraging its scale and technology to offer extensive services beyond distribution, including support for specialty and rare-disease therapies. The company's business model relies on high volume and strategically expanding into higher-margin services, such as data analytics and patient support programs. Investors are evaluating Cencora's long-term growth prospects based on pharmaceutical demand stability, cost management, and the ability of its specialized services to drive earnings.
Cencora Specialty Distribution Services - How a Quiet Backbone Keeps Critical Medicines Moving
This article details Cencora's Specialty Distribution Services, highlighting its crucial role in the logistics of complex pharmaceuticals, particularly cold-chain and limited-distribution drugs in the US. It explains how Cencora acts as a vital link between manufacturers and providers, ensuring critical medicines reach patients safely and efficiently. The service is presented as a quiet yet essential component of Cencora's business model, contributing to recurring revenue and supporting the broader pharmaceutical supply chain.
Press Release: Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release
Cencora (NYSE: COR) will release its third quarter fiscal year 2026 earnings on Wednesday, August 7, 2026. The company will also host a conference call and webcast to discuss the financial results, which will be accessible via its investor relations website.
Cencora Inc. stock outperforms competitors on strong trading day
Cencora Inc. (COR) saw its stock advance by 2.80% to $296.51 on a mixed trading day where the S&P 500 remained mostly unchanged and the Dow Jones Industrial Average rose. This marked the stock's third consecutive day of gains.
Cencora lines up Aug. 5 earnings call before NYSE opens
Cencora, Inc. (NYSE: COR) announced it will release its Third Quarter Fiscal 2026 results on Wednesday, August 5, 2026, before the New York Stock Exchange opens. The company will host a conference call at 8:30 a.m. ET to discuss the results, with President & CEO Robert P. Mauch and EVP & CFO Eva C. Boratto participating. A live webcast and replay will be available on Cencora's investor relations website, investor.cencora.com.
Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release
Cencora, Inc. (NYSE: COR) announced that it will release its Third Quarter Fiscal 2026 results on Wednesday, August 5, 2026, before the market opens. The company will host a conference call at 8:30 a.m. ET on the same day to discuss these results, featuring President & CEO Robert P. Mauch and EVP & CFO Eva C. Boratto. The live call will be webcast on investor.cencora.com, with a replay available for one year.
Cencora Inc. stock outperforms competitors on strong trading day
Cencora Inc. (COR) shares rose 1.92% to $288.42 on Wednesday, outperforming the S&P 500 Index and Dow Jones Industrial Average, which both saw declines. This marks the stock's second consecutive day of gains despite a challenging overall market session.
Cencora Inc. focuses on pharmaceutical distribution and healthcare services
Cencora Inc. plays a crucial role in the global pharmaceutical supply chain, providing distribution, specialty services, and data-driven solutions to pharmacies, hospitals, and healthcare providers. The company's business model connects drug manufacturers with care points, focusing on efficient and reliable delivery of medicines and related products. Cencora also offers support for commercialization of new therapies, inventory management, and regulatory compliance, with its operations extending internationally.
Cencora CubixxCT from Cencora Inc. - cold-chain automation for hospital pharmacies
Cencora has introduced CubixxCT, an RFID-enabled, temperature-controlled inventory management system for hospital and specialty pharmacy cold chains in the US. This system automates the tracking of high-value biologic drugs and vaccines, improving compliance, reducing waste, and integrating into existing clinical workflows. It represents Cencora's strategic move into service-based revenue beyond commodity drug wholesaling.
Cencora (COR) CFO receives 21,304 restricted stock units vesting through 2029
Cencora, Inc.'s Chief Financial Officer, Eva C. Boratto, was granted 21,304 Restricted Stock Units (RSUs) for no cash consideration. These RSUs will vest in three equal annual installments on June 29, 2027, June 29, 2028, and June 29, 2029. Following this grant, Ms. Boratto directly holds 21,304 RSUs, representing potential future share ownership contingent on the vesting schedule.
Cencora (COR) CFO files Form 3 showing small direct and trust holdings
Cencora's Chief Financial Officer, Eva C. Boratto, filed an initial Form 3, reporting a small ownership position in the company's common stock. The filing indicates 1 share held directly and 2 shares held indirectly through a trust for her spouse and children. This Form 3 establishes her initial insider holdings as an executive, fulfilling regulatory disclosure requirements.
Cencora Inc. stock underperforms Monday when compared to competitors
Cencora Inc. (COR) stock fell by 1.57% to $281.65 on Monday, underperforming the broader market. This downturn occurred despite a positive trading session where the S&P 500 Index and Dow Jones Industrial Average both saw gains. This marks the second consecutive day of losses for Cencora's stock.
Is McKesson Corporation (MCK) A Good Stock To Buy Now?
This article summarizes a bullish thesis on McKesson Corporation (MCK), arguing that its recent stock decline presents an attractive buying opportunity. The thesis highlights McKesson's dominant position in pharmaceutical distribution, its asset-light business model generating significant cash flow, and its strategic shift towards higher-margin businesses. Despite a recent revenue miss, the company's core investment thesis remains intact, with conservative estimates suggesting 18% upside and more realistic scenarios pointing to 70% upside.
Nucleus inventory solution from Cencora Inc. - modular cabinets and tighter control for specialty practices
Cencora Inc. has launched its Nucleus inventory solution, featuring modular cabinets and an integrated touchscreen to enhance real-time tracking and control for specialty physician practices, particularly in oncology. This system aims to streamline medication management, improve workflow efficiency, and provide crucial data for forecasting and reporting. The solution is currently being piloted across more than 20 specialty practice locations, reflecting Cencora's strategy to expand beyond traditional drug wholesaling into integrated healthcare solutions.
Analysts Offer Insights on Technology Companies: Remitly Global (RELY) and Adobe (ADBE)
Cantor Fitzgerald maintained a Buy rating on Remitly Global (RELY) with a $28.00 price target, noting a "Strong Buy" consensus among analysts. Piper Sandler maintained a Hold rating on Adobe (ADBE) with a $240.00 price target, with the analyst consensus also being "Hold". These ratings provide investors with recent professional opinions on two significant technology stocks.
Cencora (COR) Stock After Healthcare Supply Chain Reassessment Is The Market Overreacting
Cencora (COR) stock has been reassessed due to its role in healthcare supply chains, showing a recent share price of US$286.95 with varied returns. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 40.8%, with an estimated intrinsic value of $484.52 per share. Additionally, Cencora's P/E ratio of 21.91x is below both the industry average and Simply Wall St's proprietary "Fair Ratio" of 24.74x, further indicating it may be undervalued.
Why is Rep. Moskowitz Betting on Parker-Hannifin (PH)
Rep. Jared Moskowitz has repeatedly purchased Parker-Hannifin (PH) stock, signaling confidence in the industrial manufacturing sector, particularly aerospace. Parker-Hannifin recently reported strong Q3 results, exceeding EPS estimates, raising full-year guidance, and boasts a record $12.5 billion backlog. While congressional trades can offer insights, investors should conduct independent due diligence due to complex motivations and ongoing ethical debates surrounding lawmakers' access to information.
Price to sales forward of Cencora, Inc. – NYSE:COR
This article provides financial data for Cencora, Inc. (NYSE: COR), showing its price to sales forward value without specifying the exact figure. The content appears to be a stub or a section within a larger financial data platform like TradingView, with various navigational and informational links.
Enterprise value to EBIT forward of Cencora, Inc. – NYSE:COR
The article focuses on the "Enterprise value to EBIT forward" metric for Cencora, Inc. (NYSE: COR). It appears to be a financial data presentation page from TradingView, providing an overview of the company's financials under this specific valuation metric. The content seems to be a template for displaying financial data for a given company.
Cencora, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
This page provides an overview of Cencora, Inc. Shs Unsponsored Brazilian Depositary Receipt (C1CO34) on B3, focusing on its actual and estimated financial data. Users can explore reported financial data and analyst estimates across various statements and metrics, comparing actual results with average, high, and low estimates. The content emphasizes that this information is not investment advice and encourages users to conduct their own research.
Cencora, Inc. Actuals & Estimates (NYSE:COR)
This article provides actual and estimated financial data for Cencora, Inc. (NYSE:COR), covering income statements, balance sheets, cash flow, and valuation metrics. It details the company's stock performance, analyst forecasts, historical price movements, and upcoming earnings reports, alongside other financial statistics like market capitalization, dividends, and employee count.
Enterprise value to EBIT forward of Cencora, Inc. – LS:766149
This article displays the "Enterprise value to EBIT forward" for Cencora, Inc. (LS:766149) on TradingView. It shows that the market is currently closed with no trades. The period value, change, and change percentage are also presented on the platform.
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
This article compares AbbVie and Pfizer as investment options for 2026, focusing on their post-pandemic growth strategies, drug pipelines, and financial health. While both pharma giants face patent expirations and debt, AbbVie is highlighted for its near-term success with new immunology products and acquisitions, giving it an edge over Pfizer which relies more on potential future approvals and GLP-1 developments. The analysis includes financial metrics, risk profiles, and valuation metrics, concluding that AbbVie is the better buy for 2026.
COR Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Cencora, Inc. (COR) stock, based on analyst opinions. It details current stock performance, historical highs and lows, market capitalization, upcoming earnings reports, recent financial results including revenue and net income, dividend information, and employee count. The stock's current price is $286.95, with analysts projecting a max estimate of $412.00 and a min estimate of $285.00.
Price to earnings forward of Cencora, Inc. – NYSE:COR
The article provides a single data point for the price-to-earnings forward ratio of Cencora, Inc. (NYSE: COR). It is a brief financial snippet from TradingView, indicating a value, change, and percentage change for the specified period.
Cencora (COR) Launches Nucleus Pilot And Names A New HR Chief
Cencora (COR) has initiated a multi-site pilot for its enhanced Nucleus inventory management solution and appointed a new Chief Human Resources Officer. These strategic moves, impacting both operations and leadership, are drawing investor attention, especially given the stock's recent performance. Investors are urged to monitor updates on the pilot and the new CHRO's impact on company culture and talent strategies.
Price to earnings forward of Cencora, Inc. – LS:766149
This article provides financial information for Cencora, Inc. (LS:766149) on TradingView, specifically focusing on its Price to Earnings Forward metric. The content is presented within the context of market data from various providers like ICE Data Services and FactSet. While the article heading mentions the price to earnings forward, no specific values or changes are displayed in the provided text.
Price to book forward of Cencora, Inc. – LS:766149
This article provides financial information for Cencora, Inc. (LS:766149), specifically focusing on its "Price to book forward" metric. The content indicates the market status as closed with no recent trades and details the source of market and reference data.
Cencora (COR) director Lauren M. Tyler buys 550 shares in open market
Cencora Inc. director Lauren M. Tyler has purchased 550 shares of Common Stock in an open-market transaction at $270.23 per share. This purchase increases her direct holdings to 4,359 Cencora shares. The transaction, classified as a "P" transaction code, signifies a vote of confidence in the company by an insider.
Winners And Losers Of Q1: Cigna (NYSE:CI) Vs The Rest Of The Health Insurance Providers Stocks
This article analyzes the Q1 earnings of several health insurance providers, highlighting Cigna, CVS Health, Cencora, Oscar Health, and Centene. It discusses the industry's prospects, including tailwinds from an aging population and increasing demand for personalized healthcare, alongside challenges like regulatory scrutiny and medical cost inflation. The piece details individual company performances, noting CVS Health as the top performer and Cencora as the weakest in Q1, while also touching on broader market trends and the impact of AI and geopolitics.
Cencora Inc. stock outperforms competitors on strong trading day
Cencora Inc. (COR) stock rose 1.20% to $284.47, outperforming a mixed market day where the Dow Jones Industrial Average gained but the S&P 500 Index declined. This marks the second consecutive day of gains for the stock.
What Cardinal Health (CAH) Guidance Raise Means For Valuation
Cardinal Health (CAH) recently reported strong fiscal third-quarter earnings and raised its outlook, driven by its focus on specialty pharmaceuticals. While the company's shares have shown significant momentum and are trading at an intrinsic discount, its current P/E ratio suggests investors may be paying a premium. This article explores the valuation implications, presenting both an "undervalued" narrative and a word of caution based on earnings multiples.
Cencora (COR) Launches Nucleus Pilot And Names A New HR Chief
Cencora (COR) announced the launch of a multi-site pilot program for its enhanced Nucleus inventory management solution, aimed at specialty physician practices. Concurrently, the company named a new Chief Human Resources Officer, signaling significant operational and leadership changes. These developments are drawing investor attention as Cencora's stock has seen a 3.7% decline over the past year, and investors will be looking for updates on these strategic initiatives.
Cencora (COR) Launches Nucleus Pilot And Names A New HR Chief
Cencora (COR) has announced the pilot launch of its enhanced Nucleus inventory management solution for specialty physician practices and a new Chief Human Resources Officer. These operational and leadership changes are drawing investor attention, especially given the stock's recent performance. The Nucleus pilot aims to refine inventory and data management, while the new CHRO will focus on talent and organizational priorities.
BofA Adjusts Price Target on Cencora to $285 From $280
BofA Securities has raised its price target for Cencora (COR) shares to $285 from $280. The content includes additional financial news related to Cencora, such as new product launches, management changes, and a recent share buyback authorization. The article states that the full content is reserved for members.
Winners And Losers Of Q1: Cigna (NYSE:CI) Vs The Rest Of The Health Insurance Providers Stocks
This article analyzes the Q1 2026 performance of health insurance providers stocks, highlighting Cigna, CVS Health, Cencora, Oscar Health, and Centene. It discusses the industry's prospects, including tailwinds from an aging population and challenges like regulatory scrutiny and rising medical costs. CVS Health was noted as the best performer in Q1 with significant revenue and EPS beats, while Cencora and Oscar Health had weaker performances against analyst estimates.
Cencora Inc (COR) Financial Health: Profitability & Balance Sheet Analysis
Cencora Inc (COR) has a current financial score of 8.09, ranking 46th out of 204 in the Healthcare Equipment & Supplies industry. Despite its financial status being categorized as weak, the company shows high operating efficiency. Recent financial data indicate its latest quarterly revenue reached $78.36 billion, a 3.85% year-over-year increase, with a net profit surging by 128.64% year-over-year.
